Home › Canada › TSX stocks › PRN

Profound Medical Corp. (TSX: PRN)

PRN trades on the Toronto Stock Exchange in Life Sciences, headquartered in Ontario. Numbers below come from the TMX issuer list, Yahoo Finance closes and the Bank of Canada rate, each with its source.

Close · October 14, 2026

C$9.40

-5.91% on the day

Market cap (C$)

C$304.9M

TMX list, September 30, 2026

Market cap (US$)

US$213.8M

Micro cap at 1.4263 C$/US$

1-year return

+17.5%

-12.7% year to date

Issuer list, sector and C$ market cap: TMX Group TSX and TSXV listed companies, as of September 30, 2026. US$ figures convert C$ at 1.4263 C$ per US$, the Bank of Canada daily rate for October 14, 2026. Close and returns: Yahoo Finance daily closes for PRN.TO, last bar 2026-10-14, computed by Sophia Capital.

Profile

Field	Value
Ticker	PRN on the Toronto Stock Exchange
Yahoo symbol	PRN.TO
Sector	Life Sciences
Headquarters	Ontario
Listed	2018-07-13
Listing type	TSXV Grad
Shares outstanding	36,562,007
Also listed on	NasdaqCM
Index membership	Not in an S&P/TSX index per the TMX list
SEC CIK	0001628808
Website	No company website on record
US listing	PROF

Returns

Window	Return
1 day	-5.9%
1 week	+8.5%
1 month	+17.1%
3 months	-5.8%
6 months	+7.6%
Year to date	-12.7%
1 year	+17.5%
From 52-week high	-22.4%
52-week range	C$6.99 to C$12.11

Links

Search filings on SEDAR+TMX Money quote Yahoo Finance SEC EDGAR filings Open in the app

SEDAR+ is linked for searching only; nothing on this page is taken from it.

Recent Canadian filings by type

185 documents in 12 types. Each title links to the document at its source.

Interim financial statements (4)

Document	Type	Filed
Unaudited Interim Condensed Consolidated Financial Statements	Interim financial statements (6-K/A)	2025-03-10
Unaudited Interim Condensed Consolidated Financial Statements	Interim financial statements (6-K/A)	2025-03-10
Unaudited Interim Condensed Consolidated Financial Statements	Interim financial statements (6-K/A)	2025-03-10
Unaudited Interim Condensed Consolidated Financial Statements	Interim financial statements (6-K)	2024-11-07

MD&A (4)

Document	Type	Filed
Management’s Discussion and Analysis	MD&A (interim) (6-K/A)	2025-03-10
Management’s Discussion and Analysis	MD&A (interim) (6-K/A)	2025-03-10
Management’s Discussion and Analysis	MD&A (interim) (6-K/A)	2025-03-10
Management’s Discussion and Analysis	MD&A (interim) (6-K)	2024-11-07

Material change report (1)

Document	Type	Filed
Material Change Report, dated December 16, 2024	Material change report (6-K)	2024-12-16

News release (54)

Document	Type	Filed
PRESS RELEASE	News release (8-K)	2026-10-14
PRESS RELEASE	News release (8-K)	2026-10-09
PRESS RELEASE	News release (8-K)	2026-10-07
PRESS RELEASE	News release (8-K)	2026-09-04

Management information circular / proxy (2)

Document	Type	Filed
Management Information Circular	Management information circular (8-K)	2026-05-15
Notice of 2025 Annual and Special Meeting of Shareholders and Management Information Circular	Management information circular (8-K)	2025-04-22

Prospectus (5)

Document	Type	Filed
424B5	Prospectus supplement (424B5)	2025-12-22
SUPPL	Prospectus supplement (SUPPL)	2024-12-06
SUPPL	Prospectus supplement (SUPPL)	2024-12-05
FORM S-3	Registration statement (S-3)	2026-05-12

Annual report (2)

Document	Type	Filed
10-K Period 2025-12-31	Annual report (10-K) (10-K)	2026-03-05
10-K Period 2024-12-31	Annual report (10-K) (10-K)	2025-03-07

Quarterly report (5)

Document	Type	Filed
10-Q Period 2026-06-30	Quarterly report (10-Q) (10-Q)	2026-08-06
10-Q Period 2026-03-31	Quarterly report (10-Q) (10-Q)	2026-05-07
10-Q Period 2025-09-30	Quarterly report (10-Q) (10-Q)	2025-11-13
10-Q Period 2025-06-30	Quarterly report (10-Q) (10-Q)	2025-08-14

Early warning / ownership (2)

Document	Type	Filed
Schedule 13G amendment	Schedule 13G (SCHEDULE 13G/A)	2025-01-23
Schedule 13G amendment	Schedule 13G (SC 13G/A)	2024-11-14

Insider report (2)

Document	Type	Filed
Form 4	Form 4 (4)	2025-05-20
Form 144	Form 144 (144)	2024-11-12

Certification (29)

Document	Type	Filed
Form 52 – 109F2 – Certification of Interim Filings – CEO	Certification (52-109F2) (6-K/A)	2025-03-10
Form 52 – 109F2 – Certification of Interim Filings – CFO	Certification (52-109F2) (6-K/A)	2025-03-10
Form 52 – 109F2 – Certification of Interim Filings – CEO	Certification (52-109F2) (6-K/A)	2025-03-10
Form 52 – 109F2 – Certification of Interim Filings – CFO	Certification (52-109F2) (6-K/A)	2025-03-10

Other (75)

Document	Type	Filed
FORM 8-K	Current report (8-K) (8-K)	2026-10-14
FORM 8-K	Current report (8-K) (8-K)	2026-10-09
FORM 8-K	Current report (8-K) (8-K)	2026-10-07
FORM 8-K	Current report (8-K) (8-K)	2026-09-04

Sources: SEC EDGAR filings (public records). Documents filed only on SEDAR+ are not copied here; search SEDAR+ for the full record.

Trading halts

No CIRO halt notices for this company in our data.

Source: Canadian Investment Regulatory Organization (CIRO), Halts/Resumptions newsroom, notices since 2024-10-15.

Upcoming events

Date	Time	Event	Webcast	Source
2026-11-05	after market close	Q3 2026 earnings release	No webcast link announced	SEC filing
2026-11-05	4:30 p.m. ET	Q3 2026 earnings call	Webcast	SEC filing

Source: dates read from the company's SEC filings and newswire releases; each row links to the announcement.

US private placements (SEC Form D)

Filed	Securities	Sold	Offered	Filing
2017-10-05	Other	US$877K	US$877K	SEC EDGAR

Source: SEC EDGAR Form D filings matched on SEC CIK. Amounts are US$ as filed.

Peers in Life Sciences

Ticker	Company	Exchange	Market cap (C$)	1 month	1 year
PAIN	Vector Science and Therapeutics Corp.	TSXV	C$300.3M	-18.4%	Under a year of closes
CRDL	Cardiol Therapeutics Inc.	TSX	C$281.9M	-42.2%	+9.6%
EDT	Spectral Medical Inc.	TSX	C$335.9M	-14.0%	-20.7%
CPH	Cipher Pharmaceuticals Inc.	TSX	C$346.0M	-9.6%	-6.3%
MSCL	Satellos Bioscience Inc.	TSX	C$256.5M	-29.7%	-1.0%

The app has the price chart, every filing, private raises and the full peer set for PRN.

Open in the app